Next-Generation ROS Nanotherapy for Targeted Cancer Destruction

Produces complementary reactive oxygen species in tumors, enabling efficient tumor killing without external activation

Background

Conventional cancer treatments such as surgery, chemotherapy, and radiotherapy are often invasive, non-specific, and associated with systemic toxicity and long-term side effects. Emerging nanomedicine approaches improve targeting but frequently rely on external energy sources, limiting clinical translation and effectiveness in deep or inaccessible tumors.

Chemodynamic therapy (CDT) offers a promising alternative by leveraging tumor microenvironment conditions to generate reactive oxygen species (ROS) in situ. However, existing CDT agents are constrained by limited catalytic efficiency and the inability to generate multiple ROS types simultaneously, resulting in suboptimal therapeutic outcomes.

Technology Description
The technology is a novel metal–organic framework nanoagent, Fe(II)-TCPP, composed of ferrous ions coordinated with porphyrin ligands and synthesized via a scalable solvothermal process. The material forms nanoneedle-like structures with high surface area, enabling enhanced catalytic activity.

Fe(II)-TCPP uniquely enables dual reactive oxygen species generation within a single platform. Hydroxyl radicals are produced via Fenton reactions, while singlet oxygen is generated through the Russell mechanism. This dual-pathway activity is activated under tumor microenvironment conditions, eliminating the need for external stimulation and enabling efficient in situ tumor cell destruction.

_{Figure 1: Structural and physicochemical characterization of Cu-TCPP, Fe(III)-TCPP, and Fe(II)-TCPP.(A) Schematic illustration of the Fe(II)-TCPP synthesis strategy and resulting molecular structure. (B–F) Comparative analysis of Cu-TCPP, Fe(III)-TCPP, and Fe(II)-TCPP, including: (B) TEM images, (C) DLS size distribution, (D) zeta potential measurements, (E) UV–VIS absorption spectra, and (F) FTIR spectra. (G) High-resolution O 1s XPS spectra of TCPP and Fe(II)-TCPP. The black dashed lines indicate the characteristic binding energies of the two major oxygen species: C–OH and C═O. Green and purple curves correspond to the fitted C–OH and C═O components, respectively; the blue line represents the fitted baseline; the red line denotes the total fitted envelope; and gray dots show the experimental data. (H) XPS Fe 2p spectra of Fe(III)-TCPP and Fe(II)-TCPP for comparison of oxidation states.}

_{Figure 2: Schematic illustration of dual ROS pathways. Graphic depicting how the new CDT nanoagent works. Credit: Parinaz Ghanbari}

Further Details
Full study available at: https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202529194

Newsroom Article: New cancer-killing material developed by Oregon State University nanomedicine researchers 

Benefits

• First-in-class dual ROS-generating CDT nanoagent addressing a key limitation in the field
• No external activation required, supporting clinical feasibility and broader tumor access
• Enhanced efficacy through simultaneous ROS pathways and improved catalytic efficiency
• Selective tumor activity with minimal impact on healthy tissue
• Favorable safety profile with low cytotoxicity and strong hemocompatibility
• Demonstrated in vivo tumor suppression and prevention of recurrence in preclinical models
• Strong differentiation from existing CDT and nanomedicine platforms

Applications

• Targeted cancer therapeutics, including breast cancer
• Treatment of solid tumors across multiple indications
• Next-generation chemodynamic therapy platforms
• ROS-mediated oncology therapeutics
• Combination therapy approaches with immuno-oncology or chemotherapy

Opportunity
Available for licensing and collaborative development to advance a first-in-class nanomedicine platform with strong preclinical validation, clear mechanistic differentiation, and potential for broad oncology applications.

Status
U.S. Provisional Patent Application Filed.

This technology is supported by peer-reviewed data published in Advanced Functional Materials, demonstrating robust in vivo efficacy, tumor targeting, and dual ROS generation capability.